CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-22 | Fairmount Funds Management LLC Director | Sale | −3,500,000 | $36.40 | $127.4M | 5,503,418 |
| 2026-01-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +643 | 643 | ||
| 2025-12-26 | Kearns Evan Chief Legal Officer | Sale | −65,000 | $38.70 | $2.5M | 109,398 |
| 2025-12-26 | Green John L. Chief Financial Officer | Sale | −77,000 | $38.68 | $3.0M | 131,834 |
| 2025-12-26 | Sachs Jessica Chief Medical Officer | Sale | −82,642 | $38.70 | $3.2M | 133,938 |
| 2025-12-26 | Robinson John Edward Chief Scientific Officer | Sale | −90,000 | $38.74 | $3.5M | 140,002 |
| 2025-12-17 | Robinson John Edward Chief Scientific Officer | Grant or award | +50,000 | 50,000 | ||
| 2025-12-17 | Robinson John Edward Chief Scientific Officer | Grant or award | +320,000 | 370,000 | ||
| 2025-12-17 | Robinson John Edward Chief Scientific Officer | Shares withheld for taxes | −139,998 | $39.45 | $5.5M | 230,002 |
| 2025-12-17 | Robinson John Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-12-17 | Robbins Andrew R President and CEO | Grant or award | +185,000 | 185,000 | ||
| 2025-12-17 | Robbins Andrew R President and CEO | Grant or award | +840,000 | 1,025,000 | ||
| 2025-12-17 | Robbins Andrew R President and CEO | Shares withheld for taxes | −367,497 | $39.45 | $14.5M | 657,503 |
| 2025-12-17 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +245,000 | 245,000 | ||
| 2025-12-17 | Pinnow Cole Chief Commercial Officer | Grant or award | +50,000 | 97,450 | ||
| 2025-12-17 | Pinnow Cole Chief Commercial Officer | Grant or award | +214,000 | 311,450 | ||
| 2025-12-17 | Pinnow Cole Chief Commercial Officer | Shares withheld for taxes | −94,800 | $39.45 | $3.7M | 216,650 |
| 2025-12-17 | Pinnow Cole Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-12-17 | Sachs Jessica Chief Medical Officer | Grant or award | +50,000 | 51,296 | ||
| 2025-12-17 | Sachs Jessica Chief Medical Officer | Grant or award | +320,000 | 371,296 |
Page 2 of 7 · 131 trades